Evaluation of the combination of a biofilm-disrupting agent and negative pressure wound therapy: a case series

Thomas E Serena¹, Omar Jalodi¹, Laura Serena¹, Keyur Patel², Matthew Mynti³

¹ SerenaGroup Research Foundation, Cambridge, MA US.

JoWC, Vol. 3 0 , No. 1 , January 2021

Download Publication

Find out how to make a difference in wound care

MolecuLight Headquarters

425 University Avenue
Suite 700
Toronto, ON M5G 1T6
Canada

US Address
MolecuLight Corp.
2403 Sidney Street,
Suite 209
Pittsburgh, PA 15203

T. +1 647-362-4684
North American Toll Free:
1-877-818-4360
F.+1 647-362-4730
E: info@moleculight.com

MolecuLight is SOC ll^®
Type l Accredited:

MolecuLight awarded
Premier’s Technology
Breakthrough Designation

MolecuLight i:X
is designated as a:

MolecuLight included
in ISWCAP Consensus
Guidelines:

MolecuLight is a proud
corporate member of:

Global

USA

©2023
The MolecuLight® i:X and MolecuLightDX™ Imaging Devices are approved by Health Canada for sale in Canada and has CE marking for sale in the European Union.
The MolecuLight™ i:X and DX Imaging Devices have received FDA clearance.

Related Publications

Find out how to make a difference in wound care

MolecuLight Headquarters